Pfizer Inc has provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials for two new molecular entities. In total, the company initiated seven Phase 3 programs within the past six months.

GlaxoSmithKline (GSK) has announced the submission of two simultaneous regulatory applications to expand the use of Tyverb®/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.

Pfizer Inc announced the results of a study that found that 47 percent of smokers with a history of cardiovascular disease who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with just 13.9 percent of those given placebo. These findings were presented today at the American College of Cardiology 58th Annual Scientific Session in Orlando, Fla.

Bayer CropScience and the National Centre for Scientific Research (Centre National de la Recherche Scientifique, CNRS) in Paris, France, have renewed a framework agreement signed in 2005. The new, joint research projects pursued under this agreement are intended to contribute to ensuring a sustainable food supply for a growing world population in the context of climate change.

Novartis has announced a tender offer to acquire an additional stake of up to approximately 39% in its majority-owned Indian subsidiary, Novartis India Ltd., from public shareholders at a price of Rs 351 per share.

HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its pandemic influenza vaccine for human use Emerflu®, has been granted marketing authorization from the Australian Therapeutic Goods Administration (TGA). Emerflu® vaccine is now approved for the prevention of pandemic influenza in Australia upon official declaration of a pandemic.